Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Endocrinology|October 7, 2006
An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostateJeffrey N Miner, William Chang, Mark S Chapman, et al.
Bioorganic & Medicinal Chemistry Letters|March 18, 2004
Differentiation of in vitro transcriptional repression and activation profiles of selective glucocorticoid modulatorsSteven W Elmore, John K Pratt, Michael J Coghlan, et al.
Endocrinology|January 26, 2008
LGD-5552, an antiinflammatory glucocorticoid receptor ligand with reduced side effects, in vivoFrancisco J López, Robert J Ardecky, Bruce Bebo, et al.
Molecular Endocrinology (Baltimore, Md.)|February 15, 2003
A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effectsMichael J Coghlan, Peer B Jacobson, Ben Lane, et al.
Journal of Medicinal Chemistry|December 1, 2001
Nonsteroidal selective glucocorticoid modulators: the effect of C-5 alkyl substitution on the transcriptional activation/repression profile of 2,5-dihydro-10-methoxy-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolinesS W Elmore, M J Coghlan, D D Anderson, et al.
Families, Systems & Health : the Journal of Collaborative Family Healthcare|August 19, 2021
Posttraumatic stress disorder collaborative care: A quality improvement study in veterans affairs primary careJessica A Chen, Matthew Jakupcak, Russell McCann, et al.
Elife|March 24, 2022
Beneficial impacts of neuromuscular electrical stimulation on muscle structure and function in the zebrafish model of Duchenne muscular dystrophyElisabeth A Kilroy, Amanda C Ignacz, Kaylee L Brann, et al.
Bioorganic & Medicinal Chemistry Letters|June 8, 2007
5(Z)-benzylidene-1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-1-aza-6-oxa-chrysenes as non-steroidal glucocorticoid receptor modulatorsRobert J Ardecky, Andrew R Hudson, Dean P Phillips, et al.
Rheumatology (Oxford, England)|January 31, 2020
Systematic genetic analysis of early-onset gout: ABCG2 is the only associated locusFaseeh Zaidi, Ravi K Narang, Amanda Phipps-Green, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2015
A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced CancerAlex A Adjei, Donald A Richards, Anthony El-Khoueiry, et al.
Pageof 9